SEC Form 4 · accession 0001209191-17-022840
Horizon Pharma plc · HZNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry Moze
Officer — EVP, Chief Admin. Officer
Period of report
Mar 23, 2017
Accepted (ET)
Mar 24, 2017 · 6:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492426
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Mar 23, 2017 | M | 19,250 | — | A | 62,667 | D | |
| Ordinary Shares | Mar 23, 2017 | F | 8,798 | $14.56 | D | 53,869 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Mar 23, 2017 | M | 19,250 | D | — | — | Ordinary Shares | 19,250 | 38,500 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- F2The number of Issuer shares previously reported as beneficially owned by the reporting person was incorrectly over reported on a prior Form 4 by 195 shares of the Issuer's common stock, and has been corrected with this filing.
- F3On March 23, 2015, the reporting person was granted 77,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.